Search

Your search keyword '"O'Mahony, Deirdre"' showing total 22 results
Start Over Author "O'Mahony, Deirdre" Journal blood
22 results on '"O'Mahony, Deirdre"'

1. Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients

Author

Wilson, Matthew R., Eyre, Toby A., Kirkwood, Amy A., Wong Doo, Nicole, Soussain, Carole, Choquet, Sylvain, Martinez-Calle, Nicolás, Preston, Gavin, Ahearne, Matthew, Schorb, Elisabeth, Moles-Moreau, Marie-Pierre, Ku, Matthew, Rusconi, Chiara, Khwaja, Jahanzaib, Narkhede, Mayur, Lewis, Katharine L., Calimeri, Teresa, Durot, Eric, Renaud, Loïc, Øvlisen, Andreas Kiesbye, McIlroy, Graham, Ebsworth, Timothy J., Elliot, Johnathan, Santarsieri, Anna, Ricard, Laure, Shah, Nimish, Liu, Qin, Zayac, Adam S., Vassallo, Francesco, Lebras, Laure, Roulin, Louise, Lombion, Naelle, Manos, Kate, Fernandez, Ruben, Hamad, Nada, Lopez-Garcia, Alberto, O'Mahony, Deirdre, Gounder, Praveen, Forgeard, Nathalie, Lees, Charlotte, Agbetiafa, Kossi, Strüßmann, Tim, Htut, Thura Win, Clavert, Aline, Scott, Hamish, Guidetti, Anna, Barlow, Brett R., Tchernonog, Emmanuelle, Smith, Jeffery, Miall, Fiona, Fox, Christopher P., Cheah, Chan Y., El Galaly, Tarec Christoffer, Ferreri, Andrés J.M., Cwynarski, Kate, and McKay, Pamela

Published
2022
Full Text
View/download PDF

2. Replacing Procarbazine with Dacarbazine in Escalated Beacopp Dramatically Reduces the Post Treatment Haematopoietic Stem and Progenitor Cell Mutational Burden in Hodgkin Lymphoma Patients with No Apparent Loss of Clinical Efficacy

Author

Santarsieri, Anna, primary, Mitchell, Emily, additional, Sturgess, Katherine, additional, Brice, Pauline, additional, Menne, Tobias F., additional, Osborne, Wendy, additional, Creasey, Thomas, additional, Ardeshna, Kirit M., additional, Behan, Sarah, additional, Bhuller, Kaljit, additional, Booth, Stephen, additional, Chavda, Nikesh D., additional, Collins, Graham P., additional, Culligan, Dominic J., additional, Cwynarski, Kate, additional, Davies, Andrew, additional, Downing, Abigail, additional, Dutton, David, additional, Furtado, Michelle, additional, Gallop-Evans, Eve, additional, Hodson, Andrew, additional, Hopkins, David, additional, Hsu, Hannah, additional, Iyengar, Sunil, additional, Jones, Stephen G., additional, Linton, Kim M., additional, Lomas, Oliver C., additional, Martinez-Calle, Nicolas, additional, Mathur, Abhinav, additional, McKay, Pamela, additional, Nagumantry, Sateesh K., additional, O'Mahony, Deirdre, additional, Phillips, Elizabeth H., additional, Phillips, Neil, additional, Rudge, John F., additional, Shah, Nimish K., additional, Stafford, Gwyneth, additional, Sternberg, Alex, additional, Trickey, Rachel, additional, Uttenthal, Benjamin J., additional, Wetherall, Natasha, additional, McMillan, Andrew K., additional, Stratton, Michael, additional, Laurenti, Elisa, additional, Campbell, Peter J., additional, and Follows, George A., additional

Published
2022
Full Text
View/download PDF

6. Early Integration of High Dose Methotrexate to Frontline DLBCL Therapy Does Not Impact CNS Relapse Compared to End of Treatment Delivery: A Multicentre International Analysis of 1384 Patients

Author

Wilson, Matthew R, primary, Eyre, Toby A., additional, Kirkwood, Amy A, additional, Wong Doo, Nicole, additional, Soussain, Carole, additional, Choquet, Sylvain, additional, Martinex-Calle, Nicolas, additional, Preston, Gavin, additional, Ahearne, Matthew J, additional, Schorb, Elisabeth, additional, Moles-Moreau, Marie-Pierre, additional, Ku, Matthew, additional, Rusconi, Chiara, additional, Khwaja, Jahanzaib, additional, Narkhede, Mayur, additional, Lewis, Katharine L, additional, Calimeri, Teresa, additional, Durot, Eric, additional, Renaud, Loic, additional, Øvlisen, Andreas Kiesbye, additional, McIlroy, Graham, additional, Ebsworth, Tim, additional, Elliot, Johnathon, additional, Santarsiere, Anna, additional, Ricard, Laure, additional, Shah, Nimish, additional, Liu, Qin, additional, Zayac, Adam, additional, Vassallo, Francesco, additional, Lebras, Laure, additional, Roulin, Louise, additional, Lombion, Naelle, additional, Manos, Kate, additional, Fernandez, Ruben, additional, Hamad, Nada, additional, Lopez-Garcia, Alberto, additional, O'Mahony, Deirdre, additional, Gounder, Praveen, additional, Forgeard, Nathalie, additional, Lees, Charlotte, additional, Agbetiafa, Kossi, additional, Strüßmann, Tim, additional, Win Htut, Thura, additional, Clavert, Aline, additional, Scott, Hamish W, additional, Guidetti, Anna, additional, Barlow, Brett R, additional, Smith, Jeffrey, additional, El-Galaly, Tarec Christoffer, additional, Cheah, Chan Yoon, additional, Ferreri, Andres JM, additional, Miall, Fiona, additional, Fox, Christopher P, additional, Cwynarski, Kate, additional, and McKay, Pamela, additional

Published
2021
Full Text
View/download PDF

7. Real World Escalated Beacopdac Delivers Similar Outcomes to Escalated Beacopp and Superior Outcomes to Response-Adapted (RATHL) ABVD, While Potentially Reducing Toxicity Compared with Escalated Beacopp

Author

Santarsieri, Anna, primary, Sturgess, Katherine, additional, Brice, Pauline, additional, Menne, Tobias F, additional, Osborne, Wendy, additional, Creasey, Thomas, additional, Ardeshna, Kirit M., additional, Behan, Sarah, additional, Bhuller, Kaljit, additional, Booth, Stephen, additional, Collins, Graham P., additional, Cwynarski, Kate, additional, Davies, Andrew, additional, Furtado, Michelle, additional, Gallop-Evans, Eve, additional, Hodson, Andrew, additional, Iyengar, Sunil, additional, Jones, Stephen G, additional, Linton, Kim, additional, Martinez-Calle, Nicolas, additional, McKay, Pamela, additional, Nagumantry, Sateesh K, additional, O'Mahony, Deirdre, additional, Phillips, Beth, additional, Phillips, Neil, additional, Rudge, John F, additional, Shah, Nimish, additional, Stafford, Gwyneth, additional, Sternberg, Alex, additional, Trickey, Rachel, additional, Uttenthal, Benjamin J, additional, Wetherall, Nathasha, additional, McMillan, Andrew K, additional, and Follows, George A, additional

Published
2021
Full Text
View/download PDF

9. Procarbazine-Free Escalated Beacopdac in Frontline Therapy of Advanced Hodgkin Lymphoma Reduces Red Cell Transfusion Requirements and May Shorten Time to Menstrual Period Recovery Compared to Escalated Beacopp and Appears to be As Efficacious

Author

Santarsieri, Anna, primary, Sturgess, Katherine, additional, Brice, Pauline, additional, Menne, Tobias F, additional, Osborne, Wendy, additional, Creasey, Thomas, additional, Ardeshna, Kirit M., additional, Behan, Sarah, additional, Booth, Stephen, additional, Collins, Graham P., additional, Cwynarski, Kate, additional, Iyengar, Sunil, additional, Jones, Stephen G, additional, O'Mahony, Deirdre, additional, Martinez-Calle, Nicolas, additional, McKay, Pamela, additional, Nagumantry, Sateesh K, additional, Rudge, John, additional, Shah, Nimish, additional, Stafford, Gwyneth, additional, Sternberg, Alexander, additional, Uttenthal, Benjamin J, additional, McMillan, Andrew K, additional, and Follows, George A, additional

Published
2019
Full Text
View/download PDF

10. Yttrium-90 Radiolabeled Daclizumab, An Anti-CD25 Monoclonal Antibody, Provides Effective Therapy for Refractory and Relapsed Hodgkin's Lymphoma,

Author

Waldmann, Thomas A., primary, Janik, John, additional, Morris, John C, additional, Conlon, Kevin, additional, O'Mahony, Deirdre, additional, Pittaluga, Stefania, additional, Jaffe, Elaine S., additional, Brechbiel, Martin, additional, Paik, Chang H, additional, Chen, Clara, additional, Whatley, Millie, additional, Fleisher, Thomas A, additional, White, Jeffrey, additional, Stewart, Donn, additional, Fioravanti, Suzanne, additional, Goldman, Carolyn, additional, Bryant, Bonita, additional, Decker, Jean, additional, Junghans, Richard, additional, and Carrasquillo, Jorge A., additional

Published
2011
Full Text
View/download PDF

11. Distinct Human and Viral Interleukin-6 Profiles and Other Viral and Immunologic Abnormalities In KSHV-Associated Multicentric Castleman Disease: Relationship with Disease Activity and Individual Disease Manifestations

Author

Polizzotto, Mark N, primary, Uldrick, Thomas S, additional, Wang, Victoria, additional, Aleman, Karen, additional, Wyvill, Kathleen M, additional, Marshall, Vickie, additional, Pittaluga, Stefania, additional, O'Mahony, Deirdre, additional, Whitby, Denise, additional, Tosato, Giovanna, additional, Steinberg, Seth M., additional, Little, Richard F, additional, and Yarchoan, Robert, additional

Published
2011
Full Text
View/download PDF

13. Clinical, Biochemical, and Radiographic Responses to Rituximab Combined with Liposomal Doxorubicin (R-Dox) in HIV-Infected Patients with Severe Kaposi Sarcoma-Associated Herpes Virus (KSHV) – Associated Multicentric Castleman's Disease.

Author

Uldrick, Thomas, primary, Polizzotto, Mark N., additional, O'Mahony, Deirdre, additional, Aleman, Karen, additional, Wyvill, Kathy, additional, Steinberg, Seth, additional, Pittaluga, Stefania, additional, Little, Richard F, additional, and Yarchoan, Robert, additional

Published
2009
Full Text
View/download PDF

14. Alemtuzumab (Campath 1-H) in Patients with HTLV-1 Associated Adult T-Cell Leukemia/Lymphoma.

Author

Sharma, Kamal, primary, Janik, John E., primary, O’Mahony, Deirdre, primary, Stewart, Donn, primary, Pittaluga, Stefania, primary, Stetler-Stevenson, Maryalice, primary, Jaffe, Elaine S., primary, Raffeld, Mark, primary, Fleisher, Thomas A., primary, Lee, Cathryn C., primary, Urquhart, Nicole, primary, Steinberg, Seth, primary, Waldmann, Thomas A., primary, and Morris, John C., primary

Published
2008
Full Text
View/download PDF

15. Yttrium-90 Radiolabeled Humanized Monoclonal Antibody to CD25 in Refractory and Relapsed Hodgkin’s Lymphoma

Author

O’Mahony, Deirdre, primary, Janik, John E, primary, Carrasquillo, Jorge A., primary, Seam, Pamela, primary, Fiorillo, Joseph A, primary, Stewart, Donn, primary, Paik, Chang H, primary, Fioravanti, Suzanne, primary, Whatley, Millie, primary, Pittaluga, Stefania, primary, Brechbiel, Martin W, primary, Morris, John C, primary, and Waldmann, Thomas A, primary

Published
2008
Full Text
View/download PDF

16. Early Results of a Clinical Trial Using Targeted Oncolytic Virotherapy in Kaposi Sarcoma Herpes Virus (KSHV) Associated Multicentric Castleman’s Disease (MCD).

Author

O’Mahony, Deirdre, primary, Bernstein, Wendy, additional, Wyvill, Kathy, additional, Aleman, Karen, additional, Whitby, Denise, additional, Steinberg, Seth, additional, Tosato, Giovanna, additional, Pittaluga, Stefania, additional, Jaffe, Elaine S., additional, Yarchoan, Robert, additional, and Little, Richard F., additional

Published
2007
Full Text
View/download PDF

17. EBV-Related Lymphoproliferative Disease Complicating Therapy with Siplizumab, a Novel Anti-CD2 Mediated T- and NK-Cell Depleting Agent, in Patients with T-Cell Malignancies.

Author

O’Mahony, Deirdre, primary, Morris, John C., primary, Stetler-Stevenson, Maryalice, primary, Matthews, Helen, primary, Pittaluga, Stefania, primary, Albert, Paul, primary, Kaucic, Karen, primary, Hammershaimb, Luz, primary, Waldmann, Thomas A., primary, and Janik, John E., primary

Published
2007
Full Text
View/download PDF

22. Phase I Trial of Siplizumab in CD2-Positive Lymphoproliferative Disease.

Author

O'Mahony, Deirdre, Morris, John C., Moses, Leslie, O'Hagan, Diana, Gao, Wendy, Stetler-Stevenson, Maryalice, Taylor, Margaret, Hammershaimb, Luz, Waldmann, Thomas A., and Janik, John E.

Abstract

Siplizumab is a humanized IgG1κ class monoclonal antibody that binds to the CD2 receptor on human T- and NK-cells. In an animal model of adult T-cell leukemia/lymphoma (ATL), fifty percent of animals survived tumor challenge with 4 weeks of siplizumab treatment and the life-span of tumor bearing animals treated for six months was equivalent to that of animals not challenged with tumors. A single-center phase I dose escalation trial to assess maximum tolerated dose (MTD) and safety in patients (pts) with CD2-positive adult T-cell leukemia (ATL), cutaneous T-cell lymphoma (CTCL), peripheral T-cell lymphoma (PTCL), and large granular lymphocyte leukemia (LGL) is ongoing. Eligibility includes Karnofsky performance status ≥70%; life expectancy >2 months; appropriate hematological status and normal organ function; prior treatment with chemotherapy and monoclonal antibodies is allowed. Cohorts of 3 pts each receive escalating i.v. doses of siplizumab ranging from 0.4 to 4.8 mg/kg administered over 2–3 days per treatment week every other week for 16 weeks or until unacceptable toxicity or disease progression (PD). 16 pts have been enrolled into 5 cohorts: 0.4 (3 pts), 0.6 (3 pts), 0.8 (3 pts), 1.2 (4 pts) and 2.4 (3 pts) mg/kg per week with planned dose escalation to 3.4 and 4.8 mg/kg. Median number of courses received is 4 (range 1–8). Diagnoses include ATL (9), LGL (4), PTCL (1) and CTCL (2). Grade 1/2 infusional reactions primarily manifested as fever and chills were confined to the first dose of treatment in the majority of patients. Meperidine pretreatment significantly ameliorated infusional reactions. The median (range) percentage decrease in CD4, CD8, NK and malignant cell numbers in peripheral blood from baseline are 98(71–100%), 93(50–100%), 89(55–96%) and 88 (0–100%), respectively. No DLTs have occurred at this time. To date, 3 confirmed PRs have been observed (2 ATL, 1 LGL), 6 pts had stable disease, and 7 pts had PD. 1 pt discontinued therapy due to a siplizumab-related adverse event of polymyalgia rheumatica and 3 pts (2 ATL, 1 LGL) were removed due to CMV antigenemia (which was an off-treatment criterion at the time of study drug discontinuation). 4 patients have died during the one-year follow up period due to PD and 4 patients have completed all 8 courses of treatment. In conclusion-siplizumab has been well tolerated in this trial and the maximum tolerated dose has not been reached. The protocol has been amended to allow for treatment of CMV antigen positive patients provided oral antivirals are effective in preventing CMV disease and rising CMV levels. Anti-tumor activity has been observed in some patients. Enrollment in this study continues.

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results